Sunitinib in a MEN-1 Patient with Small Cell Neuroendocrine Tumor of the Thymus Abstract #524

Introduction: MEN-1 is an autosomal dominant disease caused by mutation of the oncosuppressor gene menin. MEN-1 is typically associated with hyperparathyroidism, islet cell tumors and pituitary adenomas, but it can also be associated with other neoplasms, such as thymic carcinoids.
Aim(s): In January 2009, a 49-year old patient diagnosed with a small cell neuroendocrine tumor of the thymus, considered inoperable. From March 2009 to March 2011, she received several systemic anti-neoplastic therapy consisting of carboplatin-etoposide, capecitabine-gemcitabine, somatostatin analogues and Everolimus. In March 2011, the patient presented progressive radiographic disease with worsening of the mediastinal syndrome. In April 2011, she was started on Sunitinib as reported in a large phase III trial on neuroendocrine tumors of the pancreas. She quickly achieved symptomatic improvement. Stable disease was detected on PET-CT scan in July 2011, which was confirmed in December 2011 by PET-CT scan.
Materials and methods: Sunitinib 50 mg/daily, 4/2 w.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Prof Giovannella Palmieri

To read results and conclusion, please login ...

Further abstracts you may be interested in

#664 Natural Course and Survival of Thymic and Bronchopulmonary Neuroendocrine Tumors are Different for Male and Female MEN-1 Patients
Introduction: The course of thymic- and bronchopulmonary neuroendocrine tumors (Th- and Bp-NET) in MEN-1 patients is still unclear.
Conference: 10th Annual ENETS Conference (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: MD Joanne De Laat
#1014 Sunitinib Induced Hypocalcaemia During Treatment of Pancreatic Neuroendocrine Tumors (pNETs)
Introduction: Sunitinib is an oral multitargeted tyrosine kinase inhibitor used for pNET treatment.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Krystallenia Alexandraki
#434 Treatment, Survival and Prognostic Markers in Patients with Thymic Carcinoids: A Clinicopathologic Study of 28 Cases
Introduction: Thymic carcinoids are uncommon but malignant tumors, usually associated with a poor prognosis. The number of cases reported is limited to a few hundred and there are few prognostic factors available.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Joakim Crona
#157 Multiple Endocrine Neoplasia Type 1 (MEN-1), Hadassah-Hebrew University Medical Center experience
Introduction: MEN 1 is an autosomal dominant genetic disorder with a prevalence of 2-4 per 100,000. The main manifestations are parathyroid (PT), gastroenteropancreatic (GEP) and pituitary tumors, but may affect other organ systems as well. MEN 1 is associated with significant morbidity and mortality, with up to 50% dying before the age of 50. Treating MEN 1 patients presents a unique diagnostic and therapeutic challenge.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Sameer Kassem
Authors: Kassem S, Glaser B, Barak D, Fraenkel M, ...
#673 MEN-1: Difficulties in Diagnosis and Therapeutic Dilemmas
Introduction: MEN1 is rare, and the most common mode of presentation is in previously identified kindred, but may be the propositus of a new kindred or a sporadic case.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Joana Saraiva
Authors: Saraiva J, Santos J, Moreno C, Alves M, ...